Alvotech (NASDAQ: ALVOW) Stock Competitors & Peer Comparison
See ALVOW's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ALVOW and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ALVOW | $0.38 | +2.68% | 3.5B | 55.38 | $0.01 | N/A |
| TAK | $18.42 | -2.33% | 60.2B | 13.59 | $1.39 | +3.34% |
| TEVA | $38.99 | -0.51% | 45.3B | 13.27 | $2.93 | N/A |
| HLN | $9.00 | -2.86% | 40.4B | 18.78 | $0.49 | +2.16% |
| ZTS | $70.68 | -0.52% | 29.9B | 10.85 | $6.58 | +2.93% |
| VTRS | $18.22 | +2.16% | 21.3B | 7.25 | $2.52 | +2.62% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.32 | +0.02% | 11.2B | 21.17 | $1.06 | N/A |
| RDY | $12.96 | +5.76% | 10.4B | 20.52 | $0.61 | +0.66% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
ALVOW vs TAK Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, TAK has a market cap of 60.2B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while TAK trades at $18.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas TAK's P/E ratio is 13.59. In terms of profitability, ALVOW's ROE is +0.77%, compared to TAK's ROE of +0.02%. Regarding short-term risk, ALVOW is less volatile compared to TAK. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
ALVOW vs TEVA Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, TEVA has a market cap of 45.3B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while TEVA trades at $38.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas TEVA's P/E ratio is 13.27. In terms of profitability, ALVOW's ROE is +0.77%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, ALVOW is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check TEVA's competition here
Haleon plc (NYSE: HLN)
ALVOW vs HLN Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, HLN has a market cap of 40.4B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while HLN trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas HLN's P/E ratio is 18.78. In terms of profitability, ALVOW's ROE is +0.77%, compared to HLN's ROE of +0.17%. Regarding short-term risk, ALVOW is less volatile compared to HLN. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
ALVOW vs ZTS Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, ZTS has a market cap of 29.9B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while ZTS trades at $70.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas ZTS's P/E ratio is 10.85. In terms of profitability, ALVOW's ROE is +0.77%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, ALVOW is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
ALVOW vs VTRS Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, VTRS has a market cap of 21.3B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while VTRS trades at $18.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas VTRS's P/E ratio is 7.25. In terms of profitability, ALVOW's ROE is +0.77%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, ALVOW is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
ALVOW vs ITCI Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ALVOW's ROE is +0.77%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, ALVOW is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
ALVOW vs CTLT Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ALVOW's ROE is +0.77%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ALVOW is less volatile compared to CTLT. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
ALVOW vs ELAN Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, ELAN has a market cap of 11.2B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while ELAN trades at $22.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas ELAN's P/E ratio is 21.17. In terms of profitability, ALVOW's ROE is +0.77%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, ALVOW is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
ALVOW vs RDY Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, RDY has a market cap of 10.4B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while RDY trades at $12.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas RDY's P/E ratio is 20.52. In terms of profitability, ALVOW's ROE is +0.77%, compared to RDY's ROE of +0.09%. Regarding short-term risk, ALVOW is less volatile compared to RDY. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
ALVOW vs ALKS Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, ALKS has a market cap of 6.7B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while ALKS trades at $40.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas ALKS's P/E ratio is 42.26. In terms of profitability, ALVOW's ROE is +0.77%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, ALVOW is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ALKS's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
ALVOW vs AMRX Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, AMRX has a market cap of 6.5B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while AMRX trades at $20.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas AMRX's P/E ratio is 22.78. In terms of profitability, ALVOW's ROE is +0.77%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, ALVOW is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check AMRX's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
ALVOW vs LNTH Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while LNTH trades at $99.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas LNTH's P/E ratio is 16.76. In terms of profitability, ALVOW's ROE is +0.77%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ALVOW is less volatile compared to LNTH. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check LNTH's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
ALVOW vs INDV Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, INDV has a market cap of 4.6B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while INDV trades at $36.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas INDV's P/E ratio is 10.10. In terms of profitability, ALVOW's ROE is +0.77%, compared to INDV's ROE of -2.16%. Regarding short-term risk, ALVOW is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check INDV's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
ALVOW vs RGC Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, RGC has a market cap of 3.1B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while RGC trades at $6.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas RGC's P/E ratio is -436.62. In terms of profitability, ALVOW's ROE is +0.77%, compared to RGC's ROE of -2.32%. Regarding short-term risk, ALVOW is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check RGC's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
ALVOW vs SUPN Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, SUPN has a market cap of 2.6B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while SUPN trades at $43.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas SUPN's P/E ratio is 14.58. In terms of profitability, ALVOW's ROE is +0.77%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, ALVOW is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check SUPN's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
ALVOW vs HCM Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while HCM trades at $14.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas HCM's P/E ratio is 5.30. In terms of profitability, ALVOW's ROE is +0.77%, compared to HCM's ROE of +0.01%. Regarding short-term risk, ALVOW is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check HCM's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
ALVOW vs DCPH Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ALVOW's ROE is +0.77%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ALVOW is less volatile compared to DCPH. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check DCPH's competition here
Bausch Health Companies Inc. (NYSE: BHC)
ALVOW vs BHC Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, BHC has a market cap of 2.2B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while BHC trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas BHC's P/E ratio is 1.47. In terms of profitability, ALVOW's ROE is +0.77%, compared to BHC's ROE of +0.89%. Regarding short-term risk, ALVOW is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check BHC's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
ALVOW vs AVDL Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ALVOW's ROE is +0.77%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, ALVOW is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check AVDL's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
ALVOW vs TRLV Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, TRLV has a market cap of 2.1B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while TRLV trades at $12.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas TRLV's P/E ratio is -5.02. In terms of profitability, ALVOW's ROE is +0.77%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, ALVOW is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check TRLV's competition here
Perrigo Company plc (NYSE: PRGO)
ALVOW vs PRGO Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, PRGO has a market cap of 2.1B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while PRGO trades at $15.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas PRGO's P/E ratio is 6.03. In terms of profitability, ALVOW's ROE is +0.77%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, ALVOW is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check PRGO's competition here
Alvotech (NASDAQ: ALVO)
ALVOW vs ALVO Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, ALVO has a market cap of 2.1B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while ALVO trades at $5.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas ALVO's P/E ratio is -10.42. In terms of profitability, ALVOW's ROE is +0.77%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, ALVOW is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ALVO's competition here
Embecta Corp. (NASDAQ: EMBCV)
ALVOW vs EMBCV Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ALVOW's ROE is +0.77%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, ALVOW is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
ALVOW vs DVAX Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ALVOW's ROE is +0.77%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ALVOW is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check DVAX's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
ALVOW vs ANIP Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while ANIP trades at $73.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas ANIP's P/E ratio is 9.10. In terms of profitability, ALVOW's ROE is +0.77%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, ALVOW is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ANIP's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
ALVOW vs ETON Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while ETON trades at $58.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas ETON's P/E ratio is 155.74. In terms of profitability, ALVOW's ROE is +0.77%, compared to ETON's ROE of +0.40%. Regarding short-term risk, ALVOW is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ETON's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
ALVOW vs TARO Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas TARO's P/E ratio is 30.05. In terms of profitability, ALVOW's ROE is +0.77%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ALVOW is less volatile compared to TARO. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
ALVOW vs PAHC Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while PAHC trades at $34.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas PAHC's P/E ratio is 12.18. In terms of profitability, ALVOW's ROE is +0.77%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, ALVOW is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check PAHC's competition here
Cronos Group Inc. (NASDAQ: CRON)
ALVOW vs CRON Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while CRON trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas CRON's P/E ratio is 17.46. In terms of profitability, ALVOW's ROE is +0.77%, compared to CRON's ROE of +0.06%. Regarding short-term risk, ALVOW is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
ALVOW vs AMPH Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, AMPH has a market cap of 1.2B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while AMPH trades at $27.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas AMPH's P/E ratio is 9.35. In terms of profitability, ALVOW's ROE is +0.77%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, ALVOW is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
ALVOW vs HROW Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while HROW trades at $31.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas HROW's P/E ratio is -31.92. In terms of profitability, ALVOW's ROE is +0.77%, compared to HROW's ROE of -1.04%. Regarding short-term risk, ALVOW is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check HROW's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
ALVOW vs PCRX Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, PCRX has a market cap of 998.7M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while PCRX trades at $25.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas PCRX's P/E ratio is 9.77. In terms of profitability, ALVOW's ROE is +0.77%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, ALVOW is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
ALVOW vs PETQ Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ALVOW's ROE is +0.77%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ALVOW is less volatile compared to PETQ. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
ALVOW vs COLL Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, COLL has a market cap of 734M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while COLL trades at $22.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas COLL's P/E ratio is 2.84. In terms of profitability, ALVOW's ROE is +0.77%, compared to COLL's ROE of +0.16%. Regarding short-term risk, ALVOW is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
ALVOW vs IRWD Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, IRWD has a market cap of 678.2M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while IRWD trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas IRWD's P/E ratio is 5.28. In terms of profitability, ALVOW's ROE is +0.77%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, ALVOW is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check IRWD's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
ALVOW vs AQST Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, AQST has a market cap of 596M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while AQST trades at $4.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas AQST's P/E ratio is -7.31. In terms of profitability, ALVOW's ROE is +0.77%, compared to AQST's ROE of +2.44%. Regarding short-term risk, ALVOW is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check AQST's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
ALVOW vs BDSI Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ALVOW's ROE is +0.77%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ALVOW is less volatile compared to BDSI. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check BDSI's competition here
Evotec SE (NASDAQ: EVO)
ALVOW vs EVO Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, EVO has a market cap of 564.8M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while EVO trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas EVO's P/E ratio is -2.25. In terms of profitability, ALVOW's ROE is +0.77%, compared to EVO's ROE of -0.27%. Regarding short-term risk, ALVOW is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check EVO's competition here
Glass House Brands Inc (NYSE: GLAS)
ALVOW vs GLAS Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, GLAS has a market cap of 529.2M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while GLAS trades at $6.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas GLAS's P/E ratio is -12.22. In terms of profitability, ALVOW's ROE is +0.77%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, ALVOW is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check GLAS's competition here
Evolus, Inc. (NASDAQ: EOLS)
ALVOW vs EOLS Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, EOLS has a market cap of 524.2M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while EOLS trades at $7.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas EOLS's P/E ratio is -25.21. In terms of profitability, ALVOW's ROE is +0.77%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, ALVOW is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check EOLS's competition here
Kamada Ltd. (NASDAQ: KMDA)
ALVOW vs KMDA Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, KMDA has a market cap of 497.3M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while KMDA trades at $8.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas KMDA's P/E ratio is 22.68. In terms of profitability, ALVOW's ROE is +0.77%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, ALVOW is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
ALVOW vs TKNO Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, TKNO has a market cap of 493.2M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while TKNO trades at $9.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas TKNO's P/E ratio is -29.68. In terms of profitability, ALVOW's ROE is +0.77%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, ALVOW is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check TKNO's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
ALVOW vs TLRY Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, TLRY has a market cap of 449.6M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while TLRY trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas TLRY's P/E ratio is -3.71. In terms of profitability, ALVOW's ROE is +0.77%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, ALVOW is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check TLRY's competition here
Canopy Growth Corporation (NASDAQ: CGC)
ALVOW vs CGC Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, CGC has a market cap of 390.7M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while CGC trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas CGC's P/E ratio is -2.07. In terms of profitability, ALVOW's ROE is +0.77%, compared to CGC's ROE of -0.33%. Regarding short-term risk, ALVOW is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check CGC's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
ALVOW vs EBS Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, EBS has a market cap of 354M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while EBS trades at $6.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas EBS's P/E ratio is 4.76. In terms of profitability, ALVOW's ROE is +0.77%, compared to EBS's ROE of -0.36%. Regarding short-term risk, ALVOW is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
ALVOW vs ALIM Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ALVOW's ROE is +0.77%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ALVOW is less volatile compared to ALIM. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
ALVOW vs LNDC Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ALVOW's ROE is +0.77%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, ALVOW is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
ALVOW vs ACB Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, ACB has a market cap of 253.3M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while ACB trades at $4.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas ACB's P/E ratio is -2.95. In terms of profitability, ALVOW's ROE is +0.77%, compared to ACB's ROE of -0.21%. Regarding short-term risk, ALVOW is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ACB's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
ALVOW vs SIGA Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, SIGA has a market cap of 248.2M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while SIGA trades at $3.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas SIGA's P/E ratio is 12.81. In terms of profitability, ALVOW's ROE is +0.77%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, ALVOW is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check SIGA's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
ALVOW vs LFCR Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, LFCR has a market cap of 244.6M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while LFCR trades at $6.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas LFCR's P/E ratio is -5.13. In terms of profitability, ALVOW's ROE is +0.77%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, ALVOW is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
ALVOW vs TYHT Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ALVOW's ROE is +0.77%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ALVOW is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check TYHT's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
ALVOW vs CRDL Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, CRDL has a market cap of 194.8M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while CRDL trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas CRDL's P/E ratio is -6.73. In terms of profitability, ALVOW's ROE is +0.77%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, ALVOW is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check CRDL's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
ALVOW vs ORGO Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, ORGO has a market cap of 177.6M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while ORGO trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas ORGO's P/E ratio is 46.00. In terms of profitability, ALVOW's ROE is +0.77%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, ALVOW is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ORGO's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
ALVOW vs REPH Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas REPH's P/E ratio is -8.04. In terms of profitability, ALVOW's ROE is +0.77%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ALVOW is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
ALVOW vs DERM Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, DERM has a market cap of 177M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while DERM trades at $6.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas DERM's P/E ratio is -29.23. In terms of profitability, ALVOW's ROE is +0.77%, compared to DERM's ROE of -0.20%. Regarding short-term risk, ALVOW is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check DERM's competition here
Theratechnologies Inc. (NASDAQ: THTX)
ALVOW vs THTX Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas THTX's P/E ratio is -28.83. In terms of profitability, ALVOW's ROE is +0.77%, compared to THTX's ROE of +0.36%. Regarding short-term risk, ALVOW is less volatile compared to THTX. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check THTX's competition here
Organigram Global Inc. (NASDAQ: OGI)
ALVOW vs OGI Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, OGI has a market cap of 152.7M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while OGI trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas OGI's P/E ratio is 2.44. In terms of profitability, ALVOW's ROE is +0.77%, compared to OGI's ROE of +0.21%. Regarding short-term risk, ALVOW is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check OGI's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
ALVOW vs ASRT Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas ASRT's P/E ratio is -7.10. In terms of profitability, ALVOW's ROE is +0.77%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, ALVOW is less volatile compared to ASRT. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
ALVOW vs SCTL Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ALVOW's ROE is +0.77%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ALVOW is less volatile compared to SCTL. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check SCTL's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
ALVOW vs CPIX Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, CPIX has a market cap of 115.7M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while CPIX trades at $7.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas CPIX's P/E ratio is -19.30. In terms of profitability, ALVOW's ROE is +0.77%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, ALVOW is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check CPIX's competition here
Procaps Group S.A. (NASDAQ: PROC)
ALVOW vs PROC Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas PROC's P/E ratio is 1.53. In terms of profitability, ALVOW's ROE is +0.77%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ALVOW is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
ALVOW vs OPTN Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ALVOW's ROE is +0.77%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, ALVOW is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
ALVOW vs ZOM Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ALVOW's ROE is +0.77%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, ALVOW is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
ALVOW vs GRVI Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ALVOW's ROE is +0.77%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, ALVOW is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check GRVI's competition here
BGM Group Ltd. (NASDAQ: BGM)
ALVOW vs BGM Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, BGM has a market cap of 88.8M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while BGM trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas BGM's P/E ratio is -1.46. In terms of profitability, ALVOW's ROE is +0.77%, compared to BGM's ROE of -0.05%. Regarding short-term risk, ALVOW is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check BGM's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
ALVOW vs ZYNE Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ALVOW's ROE is +0.77%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ALVOW is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
ALVOW vs SSIC Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ALVOW's ROE is +0.77%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ALVOW is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check SSIC's competition here
Talphera, Inc. (NASDAQ: TLPH)
ALVOW vs TLPH Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, TLPH has a market cap of 61.8M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while TLPH trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas TLPH's P/E ratio is -3.84. In terms of profitability, ALVOW's ROE is +0.77%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, ALVOW is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check TLPH's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
ALVOW vs ZYBT Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, ZYBT has a market cap of 61.6M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while ZYBT trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas ZYBT's P/E ratio is -6.32. In terms of profitability, ALVOW's ROE is +0.77%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, ALVOW is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ZYBT's competition here
The Valens Company Inc. (NASDAQ: VLNS)
ALVOW vs VLNS Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ALVOW's ROE is +0.77%, compared to VLNS's ROE of N/A. Regarding short-term risk, ALVOW is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check VLNS's competition here
InterCure Ltd. (NASDAQ: INCR)
ALVOW vs INCR Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, INCR has a market cap of 60.7M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while INCR trades at $5.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas INCR's P/E ratio is -4.92. In terms of profitability, ALVOW's ROE is +0.77%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ALVOW is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check INCR's competition here
DURECT Corporation (NASDAQ: DRRX)
ALVOW vs DRRX Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ALVOW's ROE is +0.77%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, ALVOW is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
ALVOW vs JUPW Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ALVOW's ROE is +0.77%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, ALVOW is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
ALVOW vs QLI Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas QLI's P/E ratio is -4.92. In terms of profitability, ALVOW's ROE is +0.77%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ALVOW is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check QLI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
ALVOW vs RMTI Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, RMTI has a market cap of 34.1M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while RMTI trades at $8.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas RMTI's P/E ratio is -6.44. In terms of profitability, ALVOW's ROE is +0.77%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, ALVOW is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
ALVOW vs HEXO Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ALVOW's ROE is +0.77%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ALVOW is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check HEXO's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
ALVOW vs CPHI Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, CPHI has a market cap of 29.5M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while CPHI trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas CPHI's P/E ratio is -1.69. In terms of profitability, ALVOW's ROE is +0.77%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, ALVOW is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check CPHI's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
ALVOW vs TXMD Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, TXMD has a market cap of 24.2M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while TXMD trades at $2.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas TXMD's P/E ratio is 106.47. In terms of profitability, ALVOW's ROE is +0.77%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, ALVOW is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
ALVOW vs CYTH Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ALVOW's ROE is +0.77%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ALVOW is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check CYTH's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
ALVOW vs AYTU Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, AYTU has a market cap of 23.3M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while AYTU trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas AYTU's P/E ratio is -0.47. In terms of profitability, ALVOW's ROE is +0.77%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, ALVOW is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check AYTU's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
ALVOW vs EVOK Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ALVOW's ROE is +0.77%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, ALVOW is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
ALVOW vs OPTH Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, OPTH has a market cap of 15.6M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while OPTH trades at $4.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas OPTH's P/E ratio is -3.37. In terms of profitability, ALVOW's ROE is +0.77%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, ALVOW is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
ALVOW vs ACRX Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ALVOW's ROE is +0.77%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, ALVOW is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
ALVOW vs CABR Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, CABR has a market cap of 11.3M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while CABR trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas CABR's P/E ratio is -1.59. In terms of profitability, ALVOW's ROE is +0.77%, compared to CABR's ROE of -3.86%. Regarding short-term risk, ALVOW is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
ALVOW vs AGRX Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ALVOW's ROE is +0.77%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ALVOW is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
ALVOW vs NLTX Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ALVOW's ROE is +0.77%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, ALVOW is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
ALVOW vs LCI Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas LCI's P/E ratio is -0.04. In terms of profitability, ALVOW's ROE is +0.77%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ALVOW is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
ALVOW vs ADMP Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ALVOW's ROE is +0.77%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ALVOW is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check ADMP's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
ALVOW vs GELS Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, GELS has a market cap of 5M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while GELS trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas GELS's P/E ratio is -1.09. In terms of profitability, ALVOW's ROE is +0.77%, compared to GELS's ROE of -0.25%. Regarding short-term risk, ALVOW is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check GELS's competition here
cbdMD, Inc. (AMEX: YCBD)
ALVOW vs YCBD Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, YCBD has a market cap of 4.9M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while YCBD trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas YCBD's P/E ratio is -1.14. In terms of profitability, ALVOW's ROE is +0.77%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, ALVOW is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check YCBD's competition here
Mallinckrodt plc (AMEX: MNK)
ALVOW vs MNK Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas MNK's P/E ratio is -0.44. In terms of profitability, ALVOW's ROE is +0.77%, compared to MNK's ROE of -0.36%. Regarding short-term risk, ALVOW is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
ALVOW vs FLGC Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ALVOW's ROE is +0.77%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, ALVOW is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
ALVOW vs UPC Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, UPC has a market cap of 3.1M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while UPC trades at $4.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas UPC's P/E ratio is -0.61. In terms of profitability, ALVOW's ROE is +0.77%, compared to UPC's ROE of -0.03%. Regarding short-term risk, ALVOW is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check UPC's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
ALVOW vs PLXP Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas PLXP's P/E ratio is -0.22. In terms of profitability, ALVOW's ROE is +0.77%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, ALVOW is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check PLXP's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
ALVOW vs INM Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, INM has a market cap of 2.5M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while INM trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas INM's P/E ratio is -0.25. In terms of profitability, ALVOW's ROE is +0.77%, compared to INM's ROE of -1.35%. Regarding short-term risk, ALVOW is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check INM's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
ALVOW vs SHPH Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, SHPH has a market cap of 2.4M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while SHPH trades at $3.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas SHPH's P/E ratio is -0.19. In terms of profitability, ALVOW's ROE is +0.77%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, ALVOW is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check SHPH's competition here
Athenex, Inc. (NASDAQ: ATNX)
ALVOW vs ATNX Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas ATNX's P/E ratio is -0.02. In terms of profitability, ALVOW's ROE is +0.77%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, ALVOW is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
ALVOW vs SNOA Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, SNOA has a market cap of 2.1M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while SNOA trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas SNOA's P/E ratio is -1.14. In terms of profitability, ALVOW's ROE is +0.77%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, ALVOW is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for ALVOW.Check SNOA's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
ALVOW vs PROCW Comparison September 2026
Alvotech (NASDAQ: ALVOW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALVOW stands at 3.5B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, ALVOW is priced at $0.38 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALVOW currently has a P/E ratio of 55.38, whereas PROCW's P/E ratio is N/A. In terms of profitability, ALVOW's ROE is +0.77%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, ALVOW is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for ALVOW.Check PROCW's competition here